Polyglutamine tracts: no evidence of a major role in bipolar disorder
SIR -Over the last 3 years, a large number of studies have focused on a possible role of trinucleotide repeats, particularly expanded CAG/CTG repeats, in bipolar disorder (BD). [1] [2] [3] [4] The investigation of trinucleotide repeats has been supported by reports of genetic anticipation 1 as well as studies using the repeat expansion detection (RED) technique. 2, 3 Recently, two independent studies have reported the presence of polyglutamine tracts in proteins of about 50-60 kDa extracted from lymphoblastoid cell lines of schizophrenic patients. 5, 6 In some of these cases, the polyglutamine tract appeared to co-segregate within the family with the illness. This finding is of interest, as CAG codons are translated into glutamine. In this study we tested for the presence of expanded polyglutamine tracts in a well-characterized cohort of bipolar patients. We investigated lymphoblastoid cell lines from 70 bipolar patients and 73 normal controls using Western blot analysis with 1C2-a monoclonal antibody that detects proteins containing polyglutamine tracts. 7 Patients with BD were recruited from centers that collaborate in the International Group for the Study of Lithium (IGSLI). We have focused on lithium-responsive BD, aiming to reduce genetic heterogeneity. This strategy is supported by a number of genetic-epidemiological and neuroendocrinological studies which are discussed in detail in Grof et al. 8 Control subjects for this study were 73 psychiatrically normal individuals. Of these, 34 were screened with a SADS-L interview and RDC criteria. The remaining controls were subjects without any record of psychiatric disorders whose samples were available for this study. All patients and controls were Caucasians of Western and Central European descent and were matched, whenever possible, for geographical origin. Figure 1 shows a Western blot of patients, normal controls as well as a positive control (SCA3 patient). In all cases, the 1C2 antibody detected a band of strong intensity of around 49 kDa that corresponds to the TATA-binding protein (TBP), the DNA-binding subunit of the RNA polymerase II transcription factor D. This, as well as the band of approximately 72 kDa corresponding to ataxin-3 (the expanded SCA3 protein), demonstrates the adequacy of our assay to detect polyglutamine-containing proteins. In addition, the 1C2 antibody also detected several bands of larger size (above 200 kDa) present in all individuals. These bands were interpreted as non-specific background. No difference was observed between groups. There was no evidence of a unique or more common band, regardless of intensity, that was present among patients.
The results from this study do not support the hypothesis that polyglutamine expansions play a major role in bipolar disorder. This is consistent with the findings from a previous study that investigated polyglutamine repeats in a smaller sample (18 bipolar patients) 9 and with a preliminary study conducted in four patients. 10 The ability of the 1C2 antibody to detect expanded proteins, as well as the intensity of the signal are dependent on the length, and probably concentration, of the polyglutamine sequence. Therefore, one may argue that 1C2 did not detect proteins containing polyglutamine stretches in bipolar patients because the putative pathological protein has expansions that are not long enough to be detected by this antibody. Although possible, this explanation is not consistent with the results from studies using the RED technique that predict large CAG repeats in BD. An alternative explanation is that no pathological immunoreactive bands were observed because the gene that codes for the expanded protein is not expressed (or not sufficiently expressed) in the cells analyzed. However, in all disorders described so far that are caused by expanded CAG repeats, the protein with the polyglutamine tract is always expressed in lymphoblasts. 7 Moreover, the positive results reported in schizophrenic patients were found investigating protein extracted from lymphoblasts. 5, 6 Nevertheless, a more definitive exclusion of a role of polyglutamine tracts in bipolar disorder will most likely come from studies using protein extracted from brain tissue.
Another important issue to be considered is related to the characteristics of the population studied. Patients who respond well to lithium tend to have more classical clinical features with clear episode remissions and no residual psychopathology. Thus, it is possible that including only patients who present an excellent response to lithium prophylaxis may have selected against subforms of bipolar disorder where expanded trinuceotide repeats could have a major role. On the other hand, the patients included in this study had a high recurrence risk with a high number of episodes prior to lithium treatment and a typical-not late-onset of the illness.
Finally, our findings do not necessarily exclude the role of CAG repeats in BD. It is possible that these trinucleotide repeats are implicated in the etiology of BD, but not through alterations at the protein level. This is supported by observations in other diseases with dynamic mutations such as Friedreich's ataxia and pro-gressive myoclonic epilepsy, where the repeats
